Nasdaq

FDA Approves Genentech's Evrysdi Tablet For Spinal Muscular Atrophy

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved a New Drug Application or NDA for an Evrysdi (risdiplam) tablet for people ...
The American Journal of Managed Care

Risdiplam May Be Superior for Certain SMA Type, According to Indirect Comparison

Researchers compiled data from studies of oral Evrysdi (risdiplam), Spinraza (nusinersen), and Zolgensma (onasemnogene abeparvovec), finding evidence that risdiplam may be a favorable alternative to ...
Healio

FDA approves Evrysdi tablets for spinal muscular atrophy

Please provide your email address to receive an email when new articles are posted on . Evrysdi is the only FDA-approved, noninvasive, disease-modifying treatment for spinal muscular atrophy. The ...
The New England Journal of Medicine

Risdiplam in Presymptomatic Spinal Muscular Atrophy

Risdiplam, an oral pre–messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in presymptomatic ...
Business Wire

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New ...
Nasdaq

FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and ...